Copper peptide · skin and hair · small studies
A copper peptide found in skin creams and serums, and also sold online in vials. Small skin studies give mixed results, and nobody has tested shots in people. Whether you are curious, starting, or already using it, here is what helps.

Status as of November 17, 2026. For information only, not medical advice: read the medical disclaimer.
Where are you with GHK-Cu?
Good place to start. Here is what we would want to know before deciding, in plain words.
FDA has never approved GHK-Cu, so there is no label to follow. Creams and other non-injected forms are on an FDA list pharmacies can work from for now. The injected form is on no list, and FDA plans to review it by the end of February 2027.
Every human study put it on the skin, and they were small. In the best hair result, 18 people had more eyebrow hairs on the treated side after 12 weeks. Two other trials found no benefit you could measure.
Cream results say nothing about injections. No study has tested GHK-Cu shots in people, so no one knows a safe amount. FDA says injected GHK-Cu may set off an immune reaction.
Minoxidil is an FDA-approved hair regrowth drug. No trial has compared GHK-Cu with it.
Coming Pick your questions and print them as one page.
Using it on your skin is the better-studied route. Injecting it has no human studies at all. Here is what helps with each.
The trials judged results after 12 weeks, so early weeks rarely tell you much.
The trials used their own products, such as a 2% serum or a 0.4% cream. Those are study details, not a guide for you.
No human study has tested any injected amount. Daily amounts and cycles you see online have no study behind them. If you go ahead anyway, tell your doctor first.
The calculator turns the numbers on your label into concentration and syringe units. It never suggests an amount. For clean mixing steps, see how to reconstitute peptides.
You’re using it. Here’s how to tell if it’s working and what to watch for, on the skin or by injection.
In the eyebrow trial, none of 18 people had a serious side effect or an allergic reaction. That group is too small to rule out rare reactions.
There are no human safety data for shots. Nobody has studied injection-site reactions, copper build-up or long-term use. FDA has logged 3 recalls of GHK-Cu for injection, for sterility or process problems.
No judgement. We won’t tell you where to buy or how much to take, but these steps lower the risk whatever you use:
GHK-Cu has no drug label, so there is no official list of warning signs for it. These general signs come from MedlinePlus and apply to any product.
Emergency: call 911 (or your local emergency number). Possible overdose or wrong amount: Poison Help, 1-800-222-1222, free and open 24 hours. Report a bad reaction to the FDA through MedWatch.
These can be signs of a severe allergic reaction (anaphylaxis). Call 911 or your local emergency number.
Stop using the product and wash the area with plenty of water.
There are no human data on what to expect from shots, so do not wait it out. Talk to a doctor or pharmacist, and tell them it was GHK-Cu.
Every number below says what kind of study it came from. Bracketed numbers point to the sources listed at the end.
In the eyebrow trial, each person put a 2% GHK-Cu serum on one brow. The other brow got a dummy serum. Nobody knew which was which.
Small human studyBo 2026[6]The hair count went up on the GHK-Cu side and not on the dummy side. The paper does not say by how much. Nobody had a serious side effect or an allergic reaction.
Small human studyBo 2026[6]After laser skin treatment, skin care with GHK-Cu did not reduce redness or wrinkles on objective tests. People did rate their own skin as better.
Human randomised trialMiller 2006[7]Averages from trials, not a forecast for you. Sources: Bo 2026[6], 18 adults, 2% serum on one eyebrow and a dummy serum on the other; Miller 2006[7], 13 people after laser skin treatment. Small cosmetic reports from 1998 to 2002 are left out because they were never published as full papers.
There is no label to follow. GHK-Cu has never been approved as a drug, so no FDA label tells you how to use or store it. The trials used their own products, such as a 2% serum twice a day[6] or a 0.4% cream[8]. Those are study details, not advice.
What it can and can't do for skin. One wound trial run by the product's sponsor found faster healing[9]. A second wound trial found no benefit[8]. The laser trial found no change on objective tests[7]. A 2025 review adds that GHK-Cu gets through skin poorly[10].
What it can and can't do for hair. The only direct evidence is the 18-person eyebrow trial[6]. No trial has tested GHK-Cu alone on scalp hair loss. No trial has compared it with minoxidil, an approved hair-loss treatment.
Why injection is a different question. Results from creams say nothing about shots. No study has tested injected GHK-Cu in people[11]. FDA says injected GHK-Cu may set off an immune reaction, meaning your body's defences react to it[12]. FDA has also logged 3 recalls of GHK-Cu for injection, for sterility or process problems[1].
On the skin. In the eyebrow trial, none of the 18 people had a serious side effect or an allergic reaction[6]. That is a small group, so a rare reaction would not show up.
As a shot. There are no human safety data at all. FDA's concern is a possible immune reaction to clumped peptide and impurities[12].
GHK-Cu has no drug label, and we found no official guidance on what to watch for with it, so we do not make up a GHK-Cu-specific list. The general allergy and skin-reaction signs in “Something feels off” at the top of this page come from MedlinePlus and apply to any product. If a product bothers your skin or you feel unwell, talk to a doctor or pharmacist.
This is a way to keep notes, not a medical test. The trials judged results after 12 weeks[6][7].
Any dose question belongs here. For shots, no dose has been studied, so there is no trial figure to point to.
GHK-Cu is also written GHK Cu, GHKCu or GHK.
What it is: the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine[13]. Status: not FDA approved. Topical: 503A category 1, non-injectable routes only, since May 2026. Injectable: on no 503A list; an FDA advisory committee review is planned before the end of February 2027[14]. Evidence: small human studies, topical only; no human data for injection.
Topical GHK-Cu reaches small human studies. Injected GHK-Cu has no human study at all; its evidence stops at animal and cell work.
What GHK stands for. G, H and K are the one-letter codes for glycine, histidine and lysine. GHK binds copper tightly, and the copper complex is what "GHK-Cu" and "copper peptide" refer to[13]. The spellings ghkcu, ghku and ghk cu all mean the same compound.
Where it comes from. GHK was first described in 1973 as a factor in human serum that kept liver cells alive in culture (cell study)[15]. A review by its discoverer puts plasma levels at about 200 ng/mL at age 20 and about 80 ng/mL at age 60[16]; we could not trace the original measurement, so treat that figure as a review claim. A separate study measured 70.27 ng/mL in 9 people with COPD and 133.0 ng/mL in 11 healthy controls[17].
Chemistry and half-life. GHK-Cu is highly water-soluble and breaks down under basic and oxidative conditions (lab study)[18]. No human pharmacokinetic study exists, so its half-life in people is unknown. A 2026 review expects a short half-life because peptidases cut small peptides quickly, but gives no measured value[19]. Half-life figures quoted online have no source.
A 2026 systematic review of GHK-Cu as a stand-alone aesthetic treatment found 20 eligible studies: 18 preclinical and 2 randomised controlled trials[5]. Every human study we found used GHK-Cu on the skin. The table lists them all, including the ones that found nothing.
| Study | Design and size | What was applied | Result | Study type |
|---|---|---|---|---|
| Mulder 1994[9], diabetic foot ulcers | Randomised, evaluator-blinded, vehicle-controlled; n not in abstract; sponsor ran the trial | GHK-Cu gel daily vs vehicle vs standard care; strength not in abstract | Plantar ulcers: median closure 98.5% vs 60.8% with vehicle; infection 7% vs 34% | Human RCT |
| Bishop 1992[8], venous leg ulcers | Randomised, evaluator-blinded; 86 evaluable | 0.4% copper peptide cream vs silver sulfadiazine 1% vs inert cream | Negative: the copper cream did no better than the inert cream | Human RCT |
| Miller 2006[7], after CO2 laser resurfacing | Randomised, blinded evaluators; 13 completed | Skin care with vs without GHK-Cu, 12 weeks | Negative on objective measures (redness, wrinkles); patients rated skin quality better | Small human RCT |
| Bo 2026[6], sparse eyebrows | Randomised, double-blind, one brow each; 18 adults | 2% GHK-Cu serum twice daily vs placebo serum, 12 weeks | Hair count rose on the GHK-Cu side only; no effect sizes given | Small human RCT (journal not indexed in PubMed) |
Human studies of topical GHK-Cu. Where a figure is missing, the abstract does not give it and we have not read the full text.
Studies often cited for GHK-Cu that cannot isolate it. A 45-man hair trial used GHK combined with 5-aminolevulinic acid, with no copper stated[20]. Two large scalp-injection reports used mixes of 6 to 14 ingredients that included copper tripeptide[21][22]. Two open-label studies by manufacturer-employed authors tested multi-ingredient products[23][24]. None of these tells you what GHK-Cu alone does. Several cosmetic reports from 1998 to 2002 are quoted in reviews but were never published as full papers we could check, so we leave them out.
Mechanism: lab and animal only. These findings explain why GHK-Cu is studied. They do not show an effect in people.
| Finding | Model | Source | Study type |
|---|---|---|---|
| More collagen made by fibroblasts | Cell culture | [25] | Cell |
| Faster fibroblast growth; more bFGF and VEGF at 1 nM | Human fibroblasts in culture | [26] | Cell |
| Changes the activity of "at least 4,000 human genes" | Gene-expression data from cell lines, reported in a review | [16] | Cell |
| Activates SIRT1; less smoke-induced muscle loss | Mice, 0.2 and 2 mg/kg | [17] | Animal |
| Less airway remodelling | Asthmatic mice | [27] | Animal |
Skin and wound healing. The two wound trials split: one positive diabetic-ulcer trial run by the product's sponsor[9] and one negative venous-ulcer trial[8]. The small post-laser trial found no difference on objective measures[7]. A 2025 review notes that clinical studies of topical GHK-Cu are surprisingly scarce and that the peptide passes through skin poorly[10]. A phase 2 trial of a 0.1% GHK-Cu gel on skin wounds is recruiting 60 people, with primary completion expected 2027-02-14[28].
Hair. The only direct human evidence is the 18-person eyebrow trial of a 2% serum[6]. The 45-man scalp trial used GHK without stated copper, combined with another active ingredient[20]. A study often cited for hair follicle growth used AHK-Cu, a different copper peptide, on follicles in a dish[29]. No trial has measured how long GHK-Cu takes to show results on hair.
No human study of injected GHK-Cu has been published, and none is registered on ClinicalTrials.gov (searched 2026-11-17). A 2026 orthopaedic review states that no clinical data support its use for musculoskeletal conditions[11]. FDA's safety page says injected GHK-Cu may trigger immune reactions because the peptide can clump and carry impurities, and that human data are limited[12].
| Feature | Topical GHK-Cu | Injected GHK-Cu |
|---|---|---|
| Human trials | Small; mixed results[5] | None[11] |
| FDA 503A status | Category 1 since 2026-05-14[14] | On no list; advisory review due by Feb 2027[14] |
| Registered trials | [28], recruiting | None found |
| FDA safety concern | None stated for topical use | Possible immunogenicity[12] |
| FDA recalls | None found | 3 Class II recalls[1] |
These are product-quality events. They tell you about manufacturing, not about how often people react to the drug.
We found no human data on nasal or oral GHK-Cu either.
Topical strengths used in human studies. These are the products the trials applied to skin. They are not a guide for anyone.
| Study | Use | Strength | How often | How long | Study type |
|---|---|---|---|---|---|
| Bo 2026[6] | Eyebrows | 2% serum | Twice daily | 12 weeks | Small human RCT |
| Bishop 1992[8] | Venous leg ulcers | 0.4% cream | Not in abstract | Not in abstract | Human RCT |
| Mulder 1994[9] | Diabetic foot ulcers | Metered-dose gel; strength not in abstract | Daily | Not in abstract | Human RCT |
| Miller 2006[7] | After laser resurfacing | Not in abstract | Not in abstract | 12 weeks | Small human RCT |
| [28] (ongoing) | Skin wounds | 0.1% gel, about 0.5 g | Once daily | 14 days | Trial registry |
Animal and cell amounts, not converted. Lab amounts do not translate into human doses, and we do not convert them.
Figures that circulate online without a source. Daily milligram amounts, on/off schedules and multi-week cycles for injected GHK-Cu appear on many sites. We searched for the studies behind them and found none. Questions such as "how much GHK-Cu per day" or "how much in my 50s" have the same answer: no study has tested any injected amount.
Your answer is saved only in this browser so you are not asked again. See the privacy policy.
50 mg and 100 mg are common label sizes, not doses. Only the vial size is preset. Water and amount start empty.
How much bacteriostatic water to add to a 100 mg vial changes only the concentration, not the amount of peptide in the vial. For the mixing steps, see how to reconstitute peptides; for the diluent, see BAC water for peptides. The full tool is at /calculators/reconstitution.
| Source | What was reported | Rate | Study type |
|---|---|---|---|
| Mulder 1994[9], topical gel | Ulcer infection, lower with GHK-Cu | 7% vs 34% with vehicle | Human RCT |
| Bo 2026[6], 2% serum | No serious side effects or allergic reactions | 0 serious events in 18 people | Small human RCT |
| Lee 2016[20], GHK + 5-ALA (no copper stated) | No adverse events | 0 in all 3 groups | Small human RCT |
| Tanaka 2018[22], 14-ingredient scalp injection | Pain, bleeding, swelling, dizziness, itching, redness | 4.2% minor complications; cannot be attributed to GHK-Cu | Small human study |
| FDA safety page[12] | Injectable: possible immune reactions from clumping and impurities | Concern, no rate | Regulator |
| openFDA[1] | Injectable products recalled for sterility and process failures | 3 recalls; product quality, not a clinical rate | Regulator |
There are no human data on injection-site reactions, copper overload or long-term injected use. Side-effect counts from app users or forums are self-reports, not study data, and we do not include them.
No. GHK-Cu has never been approved by FDA as a drug, so it has no FDA label and no NDC. FDA treats it as a bulk substance that has been nominated for use by compounding pharmacies[14].
Class II recall of an injectable GHK-Cu vial for lack of sterility assurance (D-0141-2021).
openFDA enforcement records[1] RegulatorClass II recall of GHK-Cu for injection, all strengths, for lack of sterility assurance (D-0051-2026).
openFDA enforcement records[1] RegulatorInjectable GHK-Cu leaves FDA category 2 because its nominators withdrew it. Leaving the list does not make it legal to compound.
Frier Levitt summary of the FDA notice[30] RegulatorNon-injectable GHK-Cu is removed from category 1 after nominations are withdrawn.
FDA 503A nominated substances list[14] RegulatorA nominator clarifies it meant to withdraw only the injectable route. "GHK-Cu (except for injectable routes of administration)" returns to category 1. FDA plans to consult its advisory committee before the end of February 2027.
FDA 503A nominated substances list, updated 2026-05-14[14] RegulatorFDA advisory committee votes 8-6-1 to recommend BPC-157, KPV and TB-500 for the 503A list. GHK-Cu is not on the agenda; injectable GHK-Cu is to be reviewed separately.
DLA Piper summary of the meeting[31] RegulatorClass II recall of an injectable GHK-Cu multi-dose vial for lack of processing controls (D-0129-2027).
openFDA enforcement records[1] RegulatorHHS publishes a draft enforcement-discretion policy for compounding certain peptides. GHK-Cu is not covered.
Federal Register 91 FR 68526[32] RegulatorPlanned FDA advisory committee review of injectable GHK-Cu.
FDA 503A nominated substances list[14] RegulatorCan pharmacies compound injectable GHK-Cu? Injectable GHK-Cu is on no 503A list, and leaving category 2 did not make it eligible[14]. The HHS policy published on 2026-10-30 is a draft, and law-firm summaries of its Appendix A do not include GHK-Cu[32]. Topical GHK-Cu sits in category 1, which covers non-injectable routes only.
Does GHK-Cu have an NDC? No. An NDC is issued for marketed drug products, and no GHK-Cu drug product has FDA approval.
Sport (WADA). GHK-Cu is not named on the WADA Prohibited List[33]. The S0 catch-all for substances without government approval for human therapeutic use probably applies. Athletes should check with their anti-doping body before using it.
GHK-Cu vs minoxidil. Minoxidil is an FDA-approved over-the-counter hair regrowth drug[34]. GHK-Cu has no approval for hair, and its best hair evidence is the 18-person eyebrow trial[6]. No head-to-head human trial of GHK-Cu against minoxidil has been published. Claims that a study showed GHK-Cu beating minoxidil name no study we could find in PubMed or elsewhere.
Skin-care copper peptide vs injected GHK-Cu. All the human trials are topical. Injected GHK-Cu has no trial and three FDA recalls[1]. Results from creams and serums say nothing about injections.
GHK-Cu in blends and with other drugs. GHK-Cu is one of four peptides in the KLOW blend, which also contains KPV. No human study has tested GHK-Cu together with BPC-157, adalimumab (Humira) or any other drug.
Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.
It is a small peptide, GHK, bound to copper (Cu). G, H and K are the letters for its three amino acids: glycine, histidine and lysine[13].
No. FDA has never approved it. Creams and other non-injected forms are on an FDA list pharmacies can work from for now. The injected form is on no list[14].
Not under any current FDA list. Injected GHK-Cu is on no list, and the HHS draft policy from October 2026 leaves it out. FDA plans to review it by the end of February 2027.
No one knows. No study has tested GHK-Cu shots in people, so there is no studied dose[11].
No one knows yet. One trial of 18 people found more eyebrow hairs on the treated side[6]. No trial has compared it with minoxidil.
In the eyebrow trial, none of 18 people had a serious side effect or an allergic reaction. That group is too small to rule out rare reactions. For shots there are no human safety data, and FDA flags a possible immune reaction.
It is not named on the WADA list. But WADA’s S0 rule for unapproved substances probably covers it. Check with your anti-doping body.